In this study, we investigated the capacity of CD133-targeted 89Zr immuno-PET to noninvasively monitor celecoxib treatment-induced changes in endogenous CD133 protein expression on colon cancer cells and tumors. Here, PROM1 is linked to malignant colon neoplasm.